SOUTH SAN FRANCISCO, Calif.,
May 26, 2020 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Jefferies Virtual Healthcare Conference on
Wednesday, June 3, 2020 at
1:30 p.m. Eastern Time.
To access the live and subsequently archived webcast, go to the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product has been approved by the European Commission for the
treatment of chronic immune thrombocytopenia in adult patients who
are refractory to other treatments and will be marketed in
Europe under the name
TAVLESSE® (fostamatinib).
Rigel's clinical programs include a Phase 3 study of
fostamatinib in warm autoimmune hemolytic anemia (AIHA); a
completed Phase 1 study of R8351, a proprietary molecule
from its interleukin receptor associated kinase (IRAK) inhibitor
program; and an ongoing Phase 1 study of R5521, a
proprietary molecule from its receptor-interacting protein kinase
(RIP) inhibitor program. In addition, Rigel has product candidates
in clinical development with partners Aclaris Therapeutics,
AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1This product candidate is investigational and has
not been established safe or effective by the U.S. Food and Drug
Administration (FDA) or any regulatory authority.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-301064907.html
SOURCE Rigel Pharmaceuticals, Inc.